Literature DB >> 11269944

Upregulation of 9 genes, including that for thioredoxin, during epithelial differentiation of mesothelioma cells.

X Sun1, K Dobra, M Björnstedt, A Hjerpe.   

Abstract

Malignant mesothelioma is a tumour originating from mesothelial cells, and it exhibits epithelial, fibrous, or biphasic differentiation. This tumour is highly resistant to therapy, and presence of a sarcomatous growth pattern has been associated with worse prognosis. A mesothelioma cell line with retained ability to differentiate into either epithelial or fibroblast-like phenotype was subjected to subtractive hybridisation in order to identify the genes coupled to tumour cell differentiation. Nine genes were found to be selectively overexpressed in the epithelial sub-line, compared to only two genes in the fibroblast-like phenotype. This may support the idea that the sarcomatous phenotype represents a less differentiated tumour. One of the genes that is differentially expressed by the epithelial cells was thioredoxin, a small redox-active protein associated with cell-growth and differentiation. This overexpression was accompanied by increased protein levels both intracellularly and in the medium. Thioredoxin is reduced by the selenoprotein thioredoxin reductase and NADPH. The activity of this enzyme was high in both cell sub-lines but induced 2-fold in the epithelially-differentiated cells. Overexpression of thioredoxin might be a factor behind the poor prognosis and reduced responsiveness to therapy of mesotheliomas. Epithelial differentiation in this cell line has previously been linked to increased synthesis of heparan sulphate proteoglycans. The possible formation of complexes including thioredoxin, thioredoxin reductase, and heparan sulphate proteoglycans might play a role in the local control of cell growth and differentiation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11269944     DOI: 10.1046/j.1432-0436.2000.660404.x

Source DB:  PubMed          Journal:  Differentiation        ISSN: 0301-4681            Impact factor:   3.880


  13 in total

1.  Methionine sulfoxide reductase (MsrA) is a regulator of antioxidant defense and lifespan in mammals.

Authors:  J Moskovitz; S Bar-Noy; W M Williams; J Requena; B S Berlett; E R Stadtman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-23       Impact factor: 11.205

Review 2.  Cellular and molecular parameters of mesothelioma.

Authors:  Maria E Ramos-Nino; Joseph R Testa; Deborah A Altomare; Harvey I Pass; Michele Carbone; Maurizio Bocchetta; Brooke T Mossman
Journal:  J Cell Biochem       Date:  2006-07-01       Impact factor: 4.429

3.  An extracellular signal-regulated kinase 2 survival pathway mediates resistance of human mesothelioma cells to asbestos-induced injury.

Authors:  Arti Shukla; Trisha F Barrett; Maximilian B MacPherson; Jedd M Hillegass; Naomi K Fukagawa; William A Swain; Kenneth J O'Byrne; Joseph R Testa; Harvey I Pass; Stephen P Faux; Brooke T Mossman
Journal:  Am J Respir Cell Mol Biol       Date:  2011-03-31       Impact factor: 6.914

4.  Phenotype-dependent apoptosis signalling in mesothelioma cells after selenite exposure.

Authors:  Gustav Nilsonne; Eric Olm; Adam Szulkin; Filip Mundt; Agnes Stein; Branka Kocic; Anna-Klara Rundlöf; Aristi P Fernandes; Mikael Björnstedt; Katalin Dobra
Journal:  J Exp Clin Cancer Res       Date:  2009-06-29

Review 5.  Current therapy for malignant mesothelioma.

Authors:  W Roy Smythe
Journal:  Curr Oncol Rep       Date:  2002-07       Impact factor: 5.945

6.  Peroxiredoxin 3 is a redox-dependent target of thiostrepton in malignant mesothelioma cells.

Authors:  Kheng Newick; Brian Cunniff; Kelsey Preston; Paul Held; Jack Arbiser; Harvey Pass; Brooke Mossman; Arti Shukla; Nicholas Heintz
Journal:  PLoS One       Date:  2012-06-25       Impact factor: 3.240

7.  Hyaluronan and N-ERC/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma.

Authors:  Filip Mundt; Gustav Nilsonne; Sertaç Arslan; Karola Csürös; Gunnar Hillerdal; Huseyin Yildirim; Muzaffer Metintas; Katalin Dobra; Anders Hjerpe
Journal:  PLoS One       Date:  2013-08-21       Impact factor: 3.240

8.  Microenvironment-Dependent Phenotypic Changes in a SCID Mouse Model for Malignant Mesothelioma.

Authors:  Eva Darai-Ramqvist; Gustav Nilsonne; Carmen Flores-Staino; Anders Hjerpe; Katalin Dobra
Journal:  Front Oncol       Date:  2013-08-09       Impact factor: 6.244

Review 9.  The role of syndecan-1 in cellular signaling and its effects on heparan sulfate biosynthesis in mesenchymal tumors.

Authors:  Tünde Szatmári; Katalin Dobra
Journal:  Front Oncol       Date:  2013-12-19       Impact factor: 6.244

10.  Variation in drug sensitivity of malignant mesothelioma cell lines with substantial effects of selenite and bortezomib, highlights need for individualized therapy.

Authors:  Adam Szulkin; Gustav Nilsonne; Filip Mundt; Agata M Wasik; Pega Souri; Anders Hjerpe; Katalin Dobra
Journal:  PLoS One       Date:  2013-06-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.